[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f5q7FZmfPE3zofDZlRIdTDKlU75Ooqys3TYpt3XgNZQU":8,"$fo0c34fel47KhNCYAGP2GOvC_7WeghCbZEOgamiaArY4":55,"$foCZp8GHE961pcn-SJpVPIrWNJeyOgqkBiXSZ4AV1TYg":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},57282,863402,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//0Rvlsm1tdkSbq5L99bjhchaojzwJ5kCw.png","华晓萍","浙江大学医学院附属妇产科医院","妇科","主治医师",94,0,"卵巢癌化疗新方案用药必读：HRD阳性方案细节全解 😷💊","","https://ystcdn.venuertc.com/venue/AI/080b5ee6-3e90-411b-a5d2-6a191d43fe41.jpg","\u003C!-- 卵巢癌HRD阳性患者化疗药品实用指南 -->\n\u003Cdiv class=\"custom-ovarychemo-guide\">\n  \u003Ch1 id=\"material_title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">卵巢癌化疗新方案用药必读：HRD阳性方案细节全解 😷💊\u003C/h1>\n  \n  \u003C!-- 引导+开篇简介 -->\n  \u003Cdiv class=\"custom-ovarychemo-section\" style=\"background: linear-gradient(90deg, #F9FBFC 60%, #E8EFF8 100%); padding: 28px 28px 16px 28px; border-radius: 14px; margin-bottom: 30px;\">\n    \u003Cp style=\"font-size: 1.2em; color: #34495E;\">\n      提起PARP抑制剂和抗血管生成药，相信不少患者朋友都听说过它们在晚期卵巢癌化疗中的应用。最近，针对HRD阳性人群的联合化疗方案有了新进展，但细节上不少地方需要特别留心。我们今天聚焦于化疗方案中两款常用药物——尼拉帕利（PARP抑制剂）和贝伐珠单抗（抗血管生成单抗），详细讲解7个关键用药细节，帮助大家科学、安全地使用药物，提升治疗效果，规避风险。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 01 药品概览与主要用途 -->\n  \u003Cdiv class=\"custom-ovarychemo-section\" style=\"background: linear-gradient(90deg, #f9f9ff 60%, #e7e9fa 100%); padding: 24px; border-radius: 14px; margin-bottom: 22px;\">\n    \u003Ch2 class=\"custom-ovarychemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">1. 药品作用简述：机制和分类 💡\u003C/h2>\n    \u003Cdiv>\n      \u003Cstrong>尼拉帕利(Niraparib)：\u003C/strong>属于PARP抑制剂，通过阻断肿瘤细胞的DNA修复通路，使异常细胞更易被杀灭。主要适用于存在同源重组修复缺陷（HRD）的患者\u003Csup>[1]\u003C/sup>。\u003Cbr>\n      \u003Cstrong>贝伐珠单抗(Bevacizumab)：\u003C/strong>是一种单克隆抗体，抑制肿瘤新生血管形成，切断肿瘤的营养供给，加速肿瘤细胞死亡。两者常与铂类化疗药物联合使用。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 02 正确的服用时间及方法 -->\n  \u003Cdiv class=\"custom-ovarychemo-section\" style=\"background: linear-gradient(90deg, #f8fefa 65%, #ebf8e7 100%); padding: 24px; border-radius: 14px; margin-bottom: 22px;\">\n    \u003Ch2 class=\"custom-ovarychemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">2. 服药时间与服用方法 ⏰\u003C/h2>\n    \u003Cul>\n      \u003Cli>\u003Cstrong>尼拉帕利：\u003C/strong>服用时间建议为每日一次，最好在每天同一时刻，晚餐后或临睡前服用最为常见。应整片吞服，不可嚼碎或掰开。用一杯水送服即可。\u003C/li>\n      \u003Cli>\u003Cstrong>贝伐珠单抗：\u003C/strong>通过静脉输注的方式给药。首次输注时间较长（约90分钟），后续可视耐受情况缩短至30-60分钟。每周期方案固定，由医护人员操作。\u003C/li>\n      \u003Cli>\u003Cstrong>用法示例：\u003C/strong>临床上一位52岁女性患者，HRD阳性、BRCA阴性，采用每日口服尼拉帕利并按照周期性输注贝伐珠单抗的联合用药方案，配合铂类药物化疗。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"custom-ovarychemo-tip\">\n      正确做法：服药前后注意每日时间一致，避免漏服，严格遵守静脉输注时长与间隔。\n    \u003C/div>\n  \u003C/div>\n  \n  \u003C!-- 03 剂型要求与服用技巧 -->\n  \u003Cdiv class=\"custom-ovarychemo-section\" style=\"background: linear-gradient(90deg, #fffdfb 68%, #faefeb 100%); padding: 24px; border-radius: 14px; margin-bottom: 22px;\">\n    \u003Ch2 class=\"custom-ovarychemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">3. 剂型特点与服用技巧 🏷️\u003C/h2>\n    \u003Cul>\n      \u003Cli>\u003Cstrong>尼拉帕利：\u003C/strong>目前市面上为胶囊或片剂剂型，主流规格为100mg与200mg。切忌自行分割或碾碎，避免影响药效。\u003C/li>\n      \u003Cli>服药时与食物关系不大，可以随餐、饭后或单独服用。若出现恶心，建议餐后服药。\u003C/li>\n      \u003Cli>\u003Cstrong>贝伐珠单抗：\u003C/strong>为无色或淡黄色澄清液体，需由专业人员经静脉点滴，普通用药者无需自行准备。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"custom-ovarychemo-tip\">\n      服用胶囊或片剂时，切记用足量清水送服，勿用果汁、碳酸饮料代替。\n    \u003C/div>\n  \u003C/div>\n  \n  \u003C!-- 04 剂量设定和调整 -->\n  \u003Cdiv class=\"custom-ovarychemo-section\" style=\"background: linear-gradient(90deg, #f7fefc 60%, #e0f8f6 100%); padding: 24px; border-radius: 14px; margin-bottom: 22px;\">\n    \u003Ch2 class=\"custom-ovarychemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">4. 剂量选择和调整 🔬\u003C/h2>\n    \u003Cul>\n      \u003Cli>\u003Cstrong>尼拉帕利：\u003C/strong>初始推荐剂量为每日300mg，对于体重低于77kg或血小板计数低于150×10\u003Csup>9\u003C/sup>/L的患者，建议初始剂量200mg/天。如遇严重不良反应，可逐步降低剂量或中断。\u003C/li>\n      \u003Cli>\u003Cstrong>贝伐珠单抗：\u003C/strong>通常采用每两至三周一次的固定剂量输注，具体剂量依据体表面积及化疗方案设计。\u003C/li>\n      \u003Cli>出现严重毒副反应（如粒细胞减少、肝功能异常），需在医生指导下进行相应调整。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"custom-ovarychemo-tip\">\n      用药期间务必按医师方案用药，不可私自调整剂量。\n    \u003C/div>\n  \u003C/div>\n  \n  \u003C!-- 05 药物相互作用及配伍注意 -->\n  \u003Cdiv class=\"custom-ovarychemo-section\" style=\"background: linear-gradient(90deg, #fef9fb 70%, #f7eefa 100%); padding: 24px; border-radius: 14px; margin-bottom: 22px;\">\n    \u003Ch2 class=\"custom-ovarychemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">5. 药物相互作用 💥\u003C/h2>\n    \u003Cul>\n      \u003Cli>\u003Cstrong>尼拉帕利：\u003C/strong>与影响肝酶活性的药物（如某些抗生素、抗癫痫药）可能产生相互作用，影响药效或副作用风险。服用尼拉帕利期间应避免与强CYP3A4抑制或诱导药物同用。\u003C/li>\n      \u003Cli>需间隔服用的药物如抗酸药，最好与其分开至少2小时。\u003C/li>\n      \u003Cli>\u003Cstrong>贝伐珠单抗：\u003C/strong>与其他化疗药物联合时，部分药物可加重血液毒性风险，需严格按方案执行。与抗凝药物同用时增加出血风险，应充分评估。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"custom-ovarychemo-tip\">\n      用药前建议将正在服用的所有处方、非处方药、保健品详细告知医师或药师，必要时调整用药顺序。\n    \u003C/div>\n  \u003C/div>\n  \n  \u003C!-- 06 常见不良反应及处理 -->\n  \u003Cdiv class=\"custom-ovarychemo-section\" style=\"background: linear-gradient(90deg, #fcf8f8 60%, #f4f2ea 100%); padding: 24px; border-radius: 14px; margin-bottom: 22px;\">\n    \u003Ch2 class=\"custom-ovarychemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">6. 常见不良反应以及处理 🛡️\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>尼拉帕利：\u003C/strong>最常见副作用为血液系统毒性，包括白细胞减少（中性粒细胞、血小板）、贫血。部分患者出现恶心、呕吐、乏力、头痛、肠胃不适等。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>贝伐珠单抗：\u003C/strong>易出现高血压、蛋白尿、出血、静脉血栓、口腔溃疡和创口愈合延迟等。极少数可影响心脏功能。\n      \u003C/li>\n      \u003Cli>\n        II/III级以上毒性如血小板明显下降、高血压难以控制时，需暂停用药并及时就医。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>临床案例：\u003C/strong>有位患者在尼拉帕利应用过程中出现III级中性粒细胞减少，实验性数据显示需要辅以升白细胞药物，并考虑调整尼拉帕利剂量。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"custom-ovarychemo-tip\">\n      正确做法：用药早期及剂量调整时，每周一次复查血常规，监测肝肾功能和血压，根据结果及时沟通医生，未出现严重不良反应前勿随意停药。\n    \u003C/div>\n  \u003C/div>\n  \n  \u003C!-- 07 用药禁忌及特殊人群 -->\n  \u003Cdiv class=\"custom-ovarychemo-section\" style=\"background: linear-gradient(90deg, #f8f7fa 56%, #e2ecfa 100%); padding: 24px; border-radius: 14px; margin-bottom: 22px;\">\n    \u003Ch2 class=\"custom-ovarychemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">7. 用药禁忌与特殊人群提醒 🚦\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>尼拉帕利：\u003C/strong>禁用于妊娠期女性及哺乳女性。肝肾功能明显异常、严重骨髓抑制者慎用。对药物有过敏史者禁止使用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>贝伐珠单抗：\u003C/strong>活动性出血、高血压未控制者、既往大手术恢复未满28天者忌用。孕妇及哺乳期女性须绝对禁用。\n      \u003C/li>\n      \u003Cli>\n        老年患者、体重偏低者或合并有肝肾疾病、慢性病史，需要在医生指导下酌情调整剂量。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"custom-ovarychemo-tip\">\n      各类禁忌需提前在用药前排查，如对药品主要成分或辅料过敏，严禁自行尝试新药。\n    \u003C/div>\n  \u003C/div>\n  \n  \u003C!-- 08 储存、过量与漏服处理 -->\n  \u003Cdiv class=\"custom-ovarychemo-section\" style=\"background: linear-gradient(90deg, #fcfaf8 60%, #edeee9 100%); padding: 24px; border-radius: 14px;\">\n    \u003Ch2 class=\"custom-ovarychemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">8. 储存要求、漏服及过量应急 🧊\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>尼拉帕利：\u003C/strong>需密封、储存在25℃以下干燥环境，避免阳光直射。开封后严防潮湿。过期药物请勿继续服用，应交由药师处理。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>漏服：\u003C/strong>若记得及时补服，但切勿一次服过多。若距下次服药时间不足12小时，则跳过漏服这次。严禁自行\"补剂量\"。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>过量：\u003C/strong>如意外过量服用，可能带来严重血液毒性、恶心呕吐等，请尽快前往医院并提供药品信息。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"custom-ovarychemo-tip\">\n      妥善保管药品，避免儿童误服。用药记得打卡或设置闹钟提醒可降低漏服风险。\n    \u003C/div>\n  \u003C/div>\n  \n  \u003C!-- 09 用药经验小结与再强调 -->\n  \u003Cdiv class=\"custom-ovarychemo-final\" style=\"background: linear-gradient(90deg, #f8fbf5 65%, #dbe8ef 100%); padding: 26px 28px 18px 28px; border-radius: 14px; margin-top: 34px; margin-bottom: 34px;\">\n    \u003Ch2 class=\"custom-ovarychemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">小结 & 用药建议🌳\u003C/h2>\n    \u003Cp style=\"font-size:1.1em;\">\n      HRD阳性卵巢癌联合化疗药物用法、剂量、相互作用及安全监测的细节至关重要。尼拉帕利和贝伐珠单抗分别以不同方式杀伤肿瘤，单独和联合使用都需按专业方案实施。\u003Cbr>\u003Cbr>\n      再次提醒：\u003Cbr>\n      1. \u003Cstrong>用药期间务必定期复诊、监测血常规和肝肾功能。\u003C/strong>\u003Cbr>\n      2. \u003Cstrong>身体有任何突发异常，切勿拖延，就医时主动说明药品信息。\u003C/strong>\u003Cbr>\n    \u003C/p>\n    \u003Cdiv class=\"custom-ovarychemo-tip\" style=\"margin-top:14px;\">\n      合理使用化疗药物、积极配合监测是实现化疗获益最大化、安全性最优的核心原则。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 10 参考文献 -->\n  \u003Cdiv class=\"custom-ovarychemo-section custom-ovarychemo-references\" style=\"background: linear-gradient(90deg, #f0fafb 70%, #dbe3ee 100%); padding: 20px; border-radius: 12px; margin-bottom: 16px;\">\n    \u003Ch2 class=\"custom-ovarychemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献\u003C/h2>\n    \u003Col class=\"custom-ovarychemo-ref-list\">\n      \u003Cli>Mirza, M. R., Monk, B. J., Herrstedt, J., et al. (2016). Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. \u003Cem>New England Journal of Medicine\u003C/em>, 375(22), 2154–2164. https://doi.org/10.1056/NEJMoa1611310\u003C/li>\n      \u003Cli>Perren, T. J., Swart, A. M., Pøhl, M., et al. (2011). A phase 3 trial of bevacizumab in ovarian cancer. \u003Cem>New England Journal of Medicine\u003C/em>, 365(26), 2484-2496. https://doi.org/10.1056/NEJMoa1103799\u003C/li>\n      \u003Cli>Moore, K., Colombo, N., Scambia, G., et al. (2018). Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. \u003Cem>New England Journal of Medicine\u003C/em>, 379(26), 2495-2505. https://doi.org/10.1056/NEJMoa1810858\u003C/li>\n      \u003Cli>Zhang, S., Royer, R., Li, S., et al. (2011). Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. \u003Cem>Gynecologic Oncology\u003C/em>, 121(2), 353-357. https://doi.org/10.1016/j.ygyno.2011.01.020\u003C/li>\n      \u003Cli>FDA. (2023). Zejula (niraparib) prescribing information. \u003Ca href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208447s015lbl.pdf\" target=\"_blank\">FDA.gov\u003C/a>\u003C/li>\n    \u003C/ol>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n/* 卵巢癌HRD阳性患者化疗方案用药 全局样式前缀：custom-ovarychemo */\n.custom-ovarychemo-guide {\n  max-width: 820px;\n  margin: 0 auto;\n  font-family: 'PingFang SC', 'Hiragino Sans GB', 'Segoe UI', Arial, sans-serif;\n  background: #fcfcfd;\n  color: #212529;\n  font-size: 17px;\n  line-height: 1.85;\n  padding-bottom: 40px;\n}\n\n.custom-ovarychemo-guide h1 {\n  font-size: 2.35em;\n  font-weight: 700;\n  margin-bottom: 22px;\n  background: linear-gradient(90deg, #E3F9F9 60%, #FFF8FD 100%);\n  border-radius: 12px;\n  padding: 22px 0 18px 28px;\n  color: #0C5A80;\n  box-shadow: 0 2px 9px rgba(28,103,145,0.09);\n}\n\n.custom-ovarychemo-section {\n  margin-bottom: 30px;\n}\n\n.custom-ovarychemo-h2 {\n  font-size: 1.45em;\n  color: #427bbd;\n  font-weight: 600;\n  margin-top: 0;\n  padding: 0 0 10px 0;\n  letter-spacing: 0.5px;\n  text-shadow: 0 1px 5px rgba(143,181,218,0.06);\n}\n\n.custom-ovarychemo-section ul,\n.custom-ovarychemo-section ol {\n  padding-left: 25px;\n  margin-bottom: 0;\n}\n\n.custom-ovarychemo-section strong {\n  color: #D65420;\n  font-weight: 600;\n}\n\n.custom-ovarychemo-tip {\n  background: #f3f8e8;\n  color: #58733b;\n  border-left: 5px solid #8fd085;\n  padding: 12px 14px;\n  border-radius: 7px;\n  font-size: 1em;\n  margin: 18px 0 3px 0;\n}\n\n.custom-ovarychemo-final {\n  box-shadow: 0 0 14px rgba(85,108,120,0.08);\n  font-size: 1.12em;\n}\n\n.custom-ovarychemo-references {\n  background: linear-gradient(90deg, #f0fafb 70%, #dbe3ee 100%);\n}\n\n.custom-ovarychemo-ref-list li {\n  font-size: 0.98em;\n  color: #3977a1;\n  line-height: 1.58;\n  margin-bottom: 7px;\n}\n\n@media (max-width: 600px) {\n  .custom-ovarychemo-guide {\n    font-size: 15.7px;\n    padding: 0 7px 30px 7px;\n  }\n  .custom-ovarychemo-guide h1 {\n    font-size: 1.55em;\n    padding-left: 12px;\n  }\n .custom-ovarychemo-h2 {\n    font-size: 1.13em;\n  }\n  .custom-ovarychemo-section {\n    padding-left: 3px!important;\n    padding-right: 3px!important;\n  }\n}\n\u003C/style>\n","\u003C!-- 卵巢癌HRD阳性患者化疗药品实用指南 -->\n\u003Cdiv class=\"custom-ovarychemo-guide\">\n  \u003Ch1 id=\"material_title\" style=\"c",520,"2025-08-08 16:34:43","卵巢癌, HRD阳性, 化疗药物, 尼拉帕利, 贝伐珠单抗, 用药注意, 常见不良反应, 联合化疗","本指南详细讲解HRD阳性卵巢癌患者的化疗用药，重点解析尼拉帕利和贝伐珠单抗的使用方式与注意事项，帮助提高化疗安全性与有效性。","2025-08-10 23:44:16",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]